Pelacarsen is an antisense therapy that is designed to reduce Lipoprotein(a) concentrations in people with high levels of the lipoprotein and who are at risk of cardiovascular disease.[1][2][3] It was developed by Ionis Pharmaceuticals and Novartis.[4]
References
edit- ^ Yeang, Calvin; Karwatowska-Prokopczuk, Ewa; Su, Fei; Dinh, Brian; Xia, Shuting; Witztum, Joseph L.; Tsimikas, Sotirios (March 2022). "Effect of Pelacarsen on Lipoprotein(a) Cholesterol and Corrected Low-Density Lipoprotein Cholesterol". Journal of the American College of Cardiology. 79 (11): 1035–1046. doi:10.1016/j.jacc.2021.12.032.
- ^ Karwatowska‑Prokopczuk, Ewa; Lesogor, Anastasia; Yan, Jing-He; Hurh, Eunju; Hoenlinger, Angelika; Margolskee, Alison; Xia, Shuting; Tsimikas, Sotirios (January 2023). "Efficacy and safety of pelacarsen in lowering Lp(a) in healthy Japanese subjects". Journal of Clinical Lipidology. 17 (1): 181–188. doi:10.1016/j.jacl.2022.12.001.
- ^ Fernandez-Prado, Raul; Perez-Gomez, Maria Vanessa; Ortiz, Alberto (1 October 2020). "Pelacarsen for lowering lipoprotein(a): implications for patients with chronic kidney disease". Clinical Kidney Journal. 13 (5): 753–757. doi:10.1093/ckj/sfaa001. PMC 7577764.
- ^ Dharma, RanjithKumar (4 August 2023). "Ionis, Novartis to develop medicine for cardiovascular disease". Pharmaceutical Technology. Retrieved 23 November 2023.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |